Does TRICARE Cover Jardiance (Empagliflozin)?

What TRICARE Plans Cover Jardiance

TRICARE covers Jardiance across its major plan types, including TRICARE Prime, TRICARE Select, TRICARE for Life, and TRICARE Reserve Select, but the out-of-pocket cost and authorization pathway differ by channel. Coverage is tied to an FDA-approved indication, so the diagnosis on your prescription must match one of the four approved uses.

Empagliflozin received its first FDA approval in 2014 for type 2 diabetes mellitus [1]. Since then, the FDA has expanded the label to include reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease (2016), reducing hospitalization for heart failure in adults with HFrEF (2021), slowing CKD progression (2023), and reducing cardiovascular death and hospitalization in HFpEF (2022) [2]. Each of those label expansions is recognized in TRICARE coverage policy because TRICARE generally mirrors FDA-approved indications for brand medications.

The TRICARE Uniform Formulary divides drugs into three tiers: generic (Tier 1), preferred brand (Tier 2), and non-preferred brand (Tier 3). Jardiance sits on Tier 3 for retail and TRICARE Mail Order Pharmacy (TMOP). Filling a 90-day supply through TMOP typically costs $60, $71 for Tier 3 drugs under TRICARE Select, versus up to $92 at a retail network pharmacy [3]. Beneficiaries who fill through a Military Treatment Facility (MTF) pharmacy pay nothing for Tier 1, 2 drugs, but Jardiance is usually not stocked at MTF pharmacies because it is a Tier 3 non-preferred brand. Confirm MTF availability at your specific installation before assuming it is free.

TRICARE for Life (TFL) beneficiaries, who are Medicare-eligible retirees, have their claims run through Medicare Part D first. If Part D denies Jardiance or if the beneficiary lacks Part D, TFL acts as secondary payer. In practice, most TFL beneficiaries obtain Jardiance through their Part D plan, which has its own formulary and PA requirements separate from TRICARE pharmacy policy [4].

Prior Authorization Criteria for Jardiance Under TRICARE

TRICARE rates Jardiance prior authorization difficulty as moderate, meaning approval is achievable with complete documentation but rarely automatic. The authorization is managed by the TRICARE pharmacy contractor (currently Express Scripts, operating as the TRICARE Pharmacy Program). Submitting an incomplete PA request is the single most common cause of delays.

For the type 2 diabetes indication, TRICARE PA reviewers typically require: a confirmed diagnosis of T2D with HbA1c documentation, evidence that metformin was tried and either failed to meet glycemic targets or was contraindicated, and a prescriber attestation that Jardiance is medically necessary [5]. An HbA1c of 7.0% or above despite metformin at maximally tolerated doses is the threshold most reviewers cite, consistent with American Diabetes Association Standards of Care 2024, which state that "for patients with type 2 diabetes and established CVD, ASCVD risk factors, heart failure, or CKD, an SGLT2 inhibitor with demonstrated benefit is recommended independent of HbA1c" [6].

For the heart failure and CKD indications, the PA criteria shift. TRICARE reviewers ask for an ejection fraction measurement (echocardiogram report), the most recent eGFR and urine albumin-to-creatinine ratio (UACR), and cardiology or nephrology specialty notes confirming the diagnosis [7]. The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death versus placebo (hazard ratio 0.62 to 95% CI 0.49, 0.77, P<0.001), which is the core evidence TRICARE uses to justify coverage under the cardiovascular indication [8]. The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the composite of cardiovascular death or hospitalization for HF by 25% (HR 0.75 to 95% CI 0.65, 0.86, P<0.001) compared with placebo [9]. Including these trial references in your PA submission supports medical necessity.

PA approvals are typically granted for 12 months, then require renewal. Set a calendar reminder 60 days before expiration to avoid a coverage gap. The prescriber's office initiates the PA; patients can check status through the TRICARE Pharmacy portal at tricare.mil or by calling Express Scripts at the number on their insurance card [3].

Step Therapy Requirements

Step therapy applies. Yes, for most TRICARE beneficiaries seeking Jardiance for type 2 diabetes, the plan requires documented failure of at least one preferred oral agent, most often metformin.

Metformin is a Tier 1 generic on the TRICARE formulary [5]. For beneficiaries with eGFR above 45 mL/min/1.73 m² and no contraindication to metformin, TRICARE expects a trial of at least 90 days at the maximum tolerated dose before authorizing a Tier 3 brand like Jardiance. The step therapy requirement is waived in specific circumstances: metformin intolerance (documented GI adverse effects), renal impairment that makes metformin contraindicated (eGFR <30 mL/min/1.73 m² per FDA labeling [2]), a concurrent diagnosis of HFrEF, HFpEF, or CKD with UACR above 200 mg/g, or an established ASCVD diagnosis paired with the prescriber's attestation that an SGLT2 inhibitor provides cardiovascular benefit independent of glycemia [6].

When step therapy is waived on cardiovascular or renal grounds, document it explicitly. A prescriber note that reads "Patient has established atherosclerotic cardiovascular disease per AHA/ACC 2019 guideline criteria; SGLT2 inhibitor indicated for cardiovascular mortality reduction per ADA 2024 Standards of Care section 9.5" is far more persuasive than a generic "medically necessary" statement [10].

For the heart failure and CKD indications, step therapy through diabetes drugs does not apply. These are distinct FDA-approved indications, and TRICARE processes them on different clinical pathways. An internist prescribing Jardiance to a non-diabetic patient with HFrEF should submit the PA under the heart failure indication (ICD-10 I50.2x), not T2D, to avoid triggering the diabetes step therapy protocol [9].

How Much Will Jardiance Cost With TRICARE?

The out-of-pocket cost varies by pharmacy channel and plan type. Understanding all three channels reduces spending.

At a TRICARE retail network pharmacy, a 30-day supply of Jardiance 10 mg costs the Tier 3 cost-share, which is roughly $47, $60 for TRICARE Prime beneficiaries and up to $92 for TRICARE Select, depending on whether the beneficiary has met their annual deductible [3]. A 90-day supply through TMOP brings that per-month cost down to approximately $20, $24. The TRICARE pharmacy benefit manager, Express Scripts, processes TMOP orders with standard 7 to 14 day delivery.

The manufacturer list price for Jardiance is approximately $680 per month for a 30-day supply of either 10 mg or 25 mg tablets [11]. Very few TRICARE beneficiaries pay list price because TRICARE's formulary cost-sharing caps out well below that figure.

A comparison of pharmacy channels for TRICARE beneficiaries:

| Channel | Supply | Approximate Cost-Share (Select) | |---|---|---| | MTF pharmacy | 90-day | $0 (if stocked) | | TMOP (mail order) | 90-day | $60, $71 | | Retail network | 30-day | Up to $92 | | Retail network | 90-day | Up to $220 |

Always call the MTF pharmacy first. Empagliflozin generic formulations are not yet widely available in the U.S. (the primary patent runs through late 2025), so the MTF may not carry it. Check formulary status quarterly.

Can I Use the Jardiance Manufacturer Savings Card With TRICARE?

No. The Boehringer Ingelheim/Lilly savings card for Jardiance, which can reduce out-of-pocket costs to as low as $10 per month for commercially insured patients, explicitly excludes all federal health care programs. Federal law (42 U.S.C. § 1320a-7b) prohibits using manufacturer coupons to reduce cost-sharing for beneficiaries of federal programs including TRICARE, Medicare, and Medicaid [12]. Using such a card despite TRICARE coverage is a federal violation, not simply a plan rule.

If cost remains a burden after exhausting TRICARE channels, two legitimate options exist. First, the Boehringer Ingelheim Patient Assistance Program (PAP) provides free medication to income-qualifying patients who lack adequate coverage; TRICARE beneficiaries who have been denied may apply [13]. Second, some patients transition to a different SGLT2 inhibitor (dapagliflozin or canagliflozin) that may be placed on a preferred tier at a lower cost-share, though clinical equivalence across indications should be confirmed with the prescriber.

How to Appeal a TRICARE Denial of Jardiance

A denial is not final. TRICARE's appeals process has three stages, and beneficiaries who submit complete documentation at Stage 1 succeed at a meaningful rate.

Stage 1: Request for Reconsideration. Submit within 90 days of the denial date. Address the reconsideration to the TRICARE pharmacy contractor (Express Scripts). The submission must include the original denial notice, a prescriber letter of medical necessity with specific clinical data (HbA1c values, EF measurement, eGFR trend, trial data references), and any relevant specialist notes [14]. The contractor must respond within 30 calendar days for standard reviews or 72 hours for expedited reviews when a delay would seriously jeopardize health.

Stage 2: TRICARE Formal Grievance. If Stage 1 fails, escalate to a formal TRICARE grievance through the Defense Health Agency (DHA). At this stage, a physician advisor who is independent of the initial reviewer evaluates the case. Provide the EMPA-REG OUTCOME citation [8], the EMPEROR-Reduced citation [9], and the CREDENCE trial (N=4,401, canagliflozin, used as a class-effect precedent for CKD) [15] as supporting evidence.

Stage 3: External Review. TRICARE beneficiaries who exhaust internal remedies may request an external review through the DHA. This process is less commonly needed; the majority of Jardiance denials that are appealed with complete cardiovascular or renal documentation resolve at Stage 1 or Stage 2.

Practical tips that improve appeal outcomes. Submit appeals via certified mail or the TRICARE secure portal to create a timestamp. Ask the prescriber to cite specific guideline language, such as the 2022 AHA/ACC Heart Failure Guideline recommendation (Class I, Level of Evidence A) for SGLT2 inhibitors in HFrEF [16]. Attach echocardiogram reports, nephrology notes, and lab values dated within the past six months.

Jardiance for Weight Loss: Does TRICARE Cover That?

TRICARE does not cover Jardiance for weight loss as a standalone indication. Empagliflozin is not FDA-approved for obesity or weight management [2]. The modest weight reduction observed in EMPA-REG OUTCOME (approximately 2 to 3 kg versus placebo) is a secondary metabolic effect, not a primary approved use [8].

TRICARE does cover GLP-1 receptor agonists approved for obesity, specifically semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound), with prior authorization and documented obesity medicine criteria (BMI 30 or above, or BMI 27 with a weight-related comorbidity) [17]. If a patient wants both an SGLT2 inhibitor for cardiovascular or renal benefit and a GLP-1 for weight loss, each drug requires its own PA under its own indication. The two authorizations are processed separately and do not conflict.

Prescribers who document Jardiance under a weight-loss indication rather than an approved cardiovascular or metabolic indication will have the PA denied, and the misdocumentation may complicate a subsequent appeal. Always list the primary FDA-approved diagnosis.

TRICARE Formulary Status and How It Changes

The TRICARE Uniform Formulary is updated quarterly by the Pharmacy and Therapeutics (P&T) Committee, a body established under 10 U.S.C. § 1074g [3]. Jardiance has held Tier 3 non-preferred brand status since its initial formulary placement. The P&T Committee can move a drug to Tier 2 if it negotiates a rebate agreement with the manufacturer or if clinical evidence supports a preferred designation.

Because generic empagliflozin is projected to enter the U.S. market in late 2025 or early 2026 (pending patent litigation outcomes), beneficiaries should anticipate a formulary tier change at that time. Generic SGLT2 inhibitors would likely be placed on Tier 1, reducing cost-share to near zero through TMOP or MTF channels. Monitor the TRICARE formulary search tool at tricare.mil/CoveredServices/Pharmacy/Formulary for updates [3].

Guideline bodies have also continued to strengthen recommendations for empagliflozin. The 2024 ADA Standards of Care state that for patients with T2D and CKD, an SGLT2 inhibitor with proven kidney benefit should be used when eGFR is 20 mL/min/1.73 m² or above [6]. That eGFR floor is lower than the 45 mL/min/1.73 m² threshold sometimes cited in older TRICARE PA criteria, which means some beneficiaries with moderate-to-advanced CKD now qualify for Jardiance under updated ADA guidance even if prior PA criteria appeared to exclude them.

Evidence Summary: Why Jardiance Is Prescribed

The clinical case for empagliflozin rests on four landmark trials that directly shaped FDA labeling and guideline recommendations.

EMPA-REG OUTCOME (N=7,020) enrolled adults with T2D and established CVD. Empagliflozin 10 mg or 25 mg reduced the three-point MACE outcome (cardiovascular death, non-fatal MI, non-fatal stroke) by 14% versus placebo (HR 0.86 to 95% CI 0.74, 0.99, P=0.04 for superiority) and cut cardiovascular mortality by 38% [8]. This trial is the foundational evidence for the cardiovascular death indication.

EMPEROR-Reduced (N=3,730) enrolled adults with HFrEF (EF 40% or below). Empagliflozin 10 mg reduced the primary composite of CV death or hospitalization for HF by 25% (HR 0.75, P<0.001) with consistent benefit regardless of diabetes status [9]. That "regardless of diabetes status" finding was decisive: it established Jardiance as a heart failure drug, not simply an antidiabetic.

EMPEROR-Preserved (N=5,988) extended the benefit to HFpEF (EF above 40%). Empagliflozin reduced CV death or HF hospitalization by 21% (HR 0.79 to 95% CI 0.69, 0.90, P<0.001) [18]. This trial supported the 2022 FDA approval for HFpEF and the corresponding AHA/ACC guideline upgrade.

EMPA-KIDNEY (N=6,609) enrolled patients with CKD (eGFR 20 to 44.9 mL/min/1.73 m²) or eGFR 45, 89.9 with UACR 200 mg/g or above, with or without diabetes. Empagliflozin 10 mg reduced the primary outcome of kidney disease progression or cardiovascular death by 28% (HR 0.72 to 95% CI 0.64, 0.82, P<0.001) [7]. The trial was stopped early for clear benefit, and the results directly supported the 2023 FDA CKD approval.

Each of these trials should be referenced in PA submissions and appeals to show that Jardiance coverage is supported by the highest level of prospective randomized evidence, not only clinical opinion.